Biocept Inc (NASDAQ:BIOC)’s share price traded up 0% during mid-day trading on Thursday . The stock traded as high as $0.36 and last traded at $0.35. 9,221,900 shares changed hands during mid-day trading, an increase of 331% from the average session volume of 2,139,261 shares. The stock had previously closed at $0.35.
Several equities analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Biocept from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a report on Monday, January 15th. Chardan Capital reissued a “buy” rating and issued a $1.50 price target (down previously from $2.50) on shares of Biocept in a report on Tuesday, November 14th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $1.75.
The company has a market capitalization of $18.19, a P/E ratio of -0.39 and a beta of 1.98. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.41 and a quick ratio of 1.27.
WARNING: This piece was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3231119/biocept-bioc-trading-0-higher.html.
Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.